AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32925319 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang scores of 5-8
Number of subjects: 115
Study 32925319 — intervention group
Group type: COMPARATOR
Intervention: STOP-Bang scores of 3-4
Number of subjects: 115
Study 32925319 — intervention group
Group type: COMPARATOR
Intervention: Alternative scoring models for STOP-Bang scores of 3-4
Number of subjects: 115
Study 32925318 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous capnography and oximetry monitoring
Number of subjects: 1335
Study 32925318 — intervention group
Group type: EXPERIMENTAL
Intervention: PRODIGY risk prediction model
Number of subjects: 1335
Study 32925337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 159
Study 32925337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 32925387 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF
Number of subjects: 106
Study 32925554 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI (mpMRI) measuring iron-corrected T1 (cT1)
Number of subjects: 81
Study 32925563 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) injected intradermally at doses of 5, 15, and 50×10 cells/administration, every 2 weeks for 3 doses.
Number of subjects: 15
Study 32925728 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week low FODMAP dietary intervention
Number of subjects: 100
Study 32925728 — intervention group
Group type: COMPARATOR
Intervention: Healthy age- and gender-matched controls
Number of subjects: 100
Study 32926343 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea patients
Number of subjects: 60
Study 32926343 — intervention group
Group type: COMPARATOR
Intervention: Non-obstructive sleep apnea patients
Number of subjects: 60
Study 32926395 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX treatment
Number of subjects: 91
Study 32926395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model (simplified by excluding SNPs)
Number of subjects: 91
Study 32926395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model with interaction terms (BMI and HAQ, BMI and erythrocyte folate)
Number of subjects: 91
Study 32926420 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV), median of four cycles (range one-16)
Number of subjects: 35
Study 32926419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 7944
Study 32926574 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq for detection of SNVs/indels
Number of subjects: 3217
Study 32926574 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq for mutation calling in genes such as PIK3CA, TP53, and ERBB2
Number of subjects: 3217
Study 32926574 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq as a clinical tool
Number of subjects: 3217
Study 32926761 — intervention group
Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) ≥0.10 in RP cohort
Number of subjects: 822
Study 32926761 — intervention group
Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) ≥0.10 in RT cohort
Number of subjects: 822
Study 32926761 — intervention group
Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) <0.10 in RP cohort
Number of subjects: 822
Study 32926761 — intervention group
Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) <0.10 in RT cohort
Number of subjects: 822
Study 32926871 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone sensor with app
Number of subjects: 320
Study 32926871 — intervention group
Group type: COMPARATOR
Intervention: Hospital reference devices
Number of subjects: 320
Study 32927016 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of orange juice (OJ)
Number of subjects: 0
Study 32928136 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemoradiation therapy (CRT)
Number of subjects: 0
Study 32928264 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy and palbociclib
Number of subjects: 103
Study 32928498 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted ultrasound following mammography for SDDs
Number of subjects: 130
Study 32928498 — intervention group
Group type: COMPARATOR
Intervention: Mammography alone for SDDs
Number of subjects: 130
Study 32928500 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve patients
Number of subjects: 56
Study 32928500 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia diagnosis
Number of subjects: 56
Study 32928500 — intervention group
Group type: COMPARATOR
Intervention: Both patients and healthy control subjects
Number of subjects: 56
Study 32928500 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 56
Study 32928517 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine administration before ICU admission
Number of subjects: 339
Study 32928517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Number of subjects: 339
Study 32928517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate concentration at ICU admission
Number of subjects: 339
Study 32928517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 339
Study 32928701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate OGTT measures (time to peak glucose >30 minutes)
Number of subjects: 52
Study 32928701 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour glucose (1hG) ≥155 mg/dL
Number of subjects: 52
Study 32928701 — intervention group
Group type: COMPARATOR
Intervention: Traditional OGTT criteria for prediabetes
Number of subjects: 52
Study 32928701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate OGTT measures (time to peak glucose and 1hG)
Number of subjects: 52
Study 32928795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, low-dose dexamethasone (LoDEX), and daratumumab
Number of subjects: 0
Study 32928796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumatinib 600 mg once daily
Number of subjects: 394
Study 32928796 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 394
Study 32928858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) treatment initiated prior to 20 weeks gestation, cessation of TDF 1 month after delivery.
Number of subjects: 170
Study 32928858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir concentrations in maternal and cord plasma measured in 10-15 women with detectable HBV DNA at delivery.
Number of subjects: 170
Study 32928858 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant HBsAg status determined at 2 months of age.
Number of subjects: 170
Study 32928858 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of adverse events including risk of flare and adherence based on pill count and questionnaire.
Number of subjects: 170
Study 32928858 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants receive HBV vaccinations at birth, 2, 4, and 6 months and hepatitis B immunoglobulin at birth if the mother is hepatitis B e antigen positive.
Number of subjects: 170
Study 32928999 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 61
Study 32928999 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 61
Study 32928999 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 61
Study 32928999 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolisation
Number of subjects: 61
Study 32928999 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolisation + SRS
Number of subjects: 61
Study 32928999 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial occlusion
Number of subjects: 61
Study 32928999 — intervention group
Group type: EXPERIMENTAL
Intervention: Different management modalities
Number of subjects: 61
Study 32929049 — intervention group
Group type: EXPERIMENTAL
Intervention: RivoCel (donor-derived T cells genetically modified with a suicide gene for iCaspase9 and truncated CD19 for cell tracking)
Number of subjects: 1
Study 32929049 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-specific CAR T cells
Number of subjects: 1
Study 32929265 — intervention group
Group type: EXPERIMENTAL
Intervention: iPSC-derived mesenchymal stromal cells (MSCs)
Number of subjects: 0
Study 32929265 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32929393 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32929477 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 123
Study 32929477 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D) with HbA1c > 8.5%
Number of subjects: 123
Study 32929477 — intervention group
Group type: COMPARATOR
Intervention: Control (without T1D)
Number of subjects: 123
Study 32929483 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients (CAF score ≥11)
Number of subjects: 604
Study 32929483 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CAF score
Number of subjects: 604
Study 32929483 — intervention group
Group type: COMPARATOR
Intervention: Non-frail patients (CAF score <11)
Number of subjects: 604
Study 32929488 — intervention group
Group type: EXPERIMENTAL
Intervention: Flotetuzumab at RP2D of 500 ng/kg per day
Number of subjects: 88
Study 32929659 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDICT app (after phase)
Number of subjects: 183
Study 32929659 — intervention group
Group type: COMPARATOR
Intervention: Standard care (before phase)
Number of subjects: 183
Study 32930023 — intervention group
Group type: EXPERIMENTAL
Intervention: Current snus users
Number of subjects: 914
Study 32930023 — intervention group
Group type: COMPARATOR
Intervention: Noncurrent snus users
Number of subjects: 914
Study 32930325 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO intake
Number of subjects: 4209
Study 32930325 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT intake
Number of subjects: 4209
Study 32930325 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/FAT ratio
Number of subjects: 4209
Study 32930325 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT1A mRNA expression
Number of subjects: 4209
Study 32930463 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with idiopathic gastroparesis over 48 weeks
Number of subjects: 138
Study 32930807 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 20
Study 32930938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-Facilitation intervention (LFI)
Number of subjects: 68
Study 32930938 — intervention group
Group type: COMPARATOR
Intervention: Matched comparison clinics (Control)
Number of subjects: 68
Study 32930969 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 32930969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32930988 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA gait assessment using a tri-axial accelerometer for 48 hours
Number of subjects: 63
Study 32931190 — intervention group
Group type: EXPERIMENTAL
Intervention: State-Trait Anxiety Inventory State ≥ 40 (moderate to severe anxiety)
Number of subjects: 391
Study 32931306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 3655
Study 32931306 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 3655
Study 32931398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib at 420 mg/d
Number of subjects: 63
Study 32931555 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased arm size
Number of subjects: 647
Study 32931555 — intervention group
Group type: COMPARATOR
Intervention: No increased arm size
Number of subjects: 647
Study 32931556 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 6 faecal calprotectin <250 mg/kg
Number of subjects: 677
Study 32931556 — intervention group
Group type: COMPARATOR
Intervention: Other Week 6 clinical assessments (clinical remission or clinical response)
Number of subjects: 677
Study 32931556 — intervention group
Group type: COMPARATOR
Intervention: Other biomarkers (CRP <5 or drug level)
Number of subjects: 677
Study 32931710 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk medication usage
Number of subjects: 543
Study 32931710 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) usage
Number of subjects: 543
Study 32931710 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of upper gastrointestinal bleeding
Number of subjects: 543
Study 32931710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 543
Study 32931958 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 602
Study 32931958 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel alone
Number of subjects: 602
Study 32931958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy
Number of subjects: 602
Study 32931958 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 602
Study 32931958 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 602
Study 32931958 — intervention group
Group type: COMPARATOR
Intervention: Clinician nonadherence to guidelines
Number of subjects: 602
Study 32933420 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission-to-groin-puncture (ATG) delay
Number of subjects: 2386
Study 32933420 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-onset-to-admission delay
Number of subjects: 2386
Study 32933420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted ATG delay
Number of subjects: 2386
Study 32933511 — intervention group
Group type: EXPERIMENTAL
Intervention: HOM group (ICCH enrollment)
Number of subjects: 2524
Study 32933511 — intervention group
Group type: COMPARATOR
Intervention: CON group (usual care)
Number of subjects: 2524
Study 32933863 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial decreases in depressive symptoms over the first two years (5.2% of participants)
Number of subjects: 2308
Study 32933863 — intervention group
Group type: COMPARATOR
Intervention: Stable low to average levels of depressive symptoms (87.0% of participants)
Number of subjects: 2308
Study 32933874 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) in combination with a new-generation drug-eluting stent (DES)
Number of subjects: 100
Study 32933920 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32933956 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of brain tissue oxygenation using invasive techniques
Number of subjects: 0
Study 32934619 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:00.000 adrenaline
Number of subjects: 95
Study 32934619 — intervention group
Group type: COMPARATOR
Intervention: 3% prilocaine with 3% felypressin (0.03 I.U. per ml)
Number of subjects: 95
Study 32934722 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy in patients with high cyclin D1 expression (cN2 stage)
Number of subjects: 232
Study 32934722 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cyclin D1 expression group
Number of subjects: 232
Study 32934722 — intervention group
Group type: COMPARATOR
Intervention: TPF induction chemotherapy
Number of subjects: 232
Study 32934758 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in TB patients
Number of subjects: 0
Study 32934758 — intervention group
Group type: EXPERIMENTAL
Intervention: TB vaccine
Number of subjects: 0
Study 32934758 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of TB and COVID-19
Number of subjects: 0
Study 32935170 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide (ABL) followed by Alendronate (ALN)
Number of subjects: 558
Study 32935170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) followed by Alendronate (ALN)
Number of subjects: 558
Study 32935287 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for 15 days
Number of subjects: 16
Study 32935287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg/day for 10 days
Number of subjects: 16
Study 32935287 — intervention group
Group type: COMPARATOR
Intervention: Balovaptan 5 mg/day alone for 10 days
Number of subjects: 16
Study 32935287 — intervention group
Group type: COMPARATOR
Intervention: Balovaptan 10 mg/day alone for 10 days
Number of subjects: 16
Study 32935623 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived mesenchymal stem cells (AD-MSCs)
Number of subjects: 0
Study 32935623 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32935662 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-based mobile-enhanced intervention (MEI)
Number of subjects: 402
Study 32935662 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 402
Study 32935936 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention over 12 months
Number of subjects: 399
Study 32935936 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI metrics
Number of subjects: 399
Study 32936868 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sugar intake (quartile 4 compared to quartile 1)
Number of subjects: 101279
Study 32936868 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugars
Number of subjects: 101279
Study 32936868 — intervention group
Group type: EXPERIMENTAL
Intervention: Free sugars
Number of subjects: 101279
Study 32936868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 101279
Study 32936868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugars from milk-based desserts
Number of subjects: 101279
Study 32936868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugars from dairy products
Number of subjects: 101279
Study 32936868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugary drinks
Number of subjects: 101279
Study 32936948 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays
Number of subjects: 1250
Study 32936949 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays (e.g., povidone iodine, nitric oxide, GLS-1200 oral spray)
Number of subjects: 700
Study 32936949 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays
Number of subjects: 700
Study 32936949 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays (if administered to patients)
Number of subjects: 700
Study 32938212 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 0
Study 32938232 — intervention group
Group type: EXPERIMENTAL
Intervention: bempegaldesleukin (BEMPEG) plus nivolumab
Number of subjects: 0
Study 32938232 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32938465 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of intentional weight loss attempts of at least five pounds
Number of subjects: 161738
Study 32938595 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilisation in people with AD, including rates of AD-associated primary care visits and specialist dermatology referrals, stratified by age, gender, socioeconomic IMD quintile, and ethnicity.
Number of subjects: 0
Study 32938595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing rates across medication classes used in AD (emollients, topical corticosteroids by potency, topical calcineurin inhibitors, topical antimicrobials, antihistamines, oral corticosteroids, and systemic immunomodulatory therapies).
Number of subjects: 0
Study 32938595 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment escalation in people first diagnosed with AD during the study period, analyzed using time-to-event analysis.
Number of subjects: 0
Study 32939030 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP3 expression in epithelial cells
Number of subjects: 0
Study 32939030 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies of LAMP3 expression
Number of subjects: 0
Study 32939046 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 40
Study 32939319 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs)
Number of subjects: 7
Study 32939459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 mg plus sofosbuvir 400 mg (daily for 12 weeks)
Number of subjects: 9
Study 32939459 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant reference group (previously enrolled in phase 2 and 3 trials)
Number of subjects: 9
Study 32939607 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat 25 mg, administered orally 3 times per week over a 28-day cycle
Number of subjects: 11
Study 32939607 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat 50 mg, administered orally 3 times per week over a 28-day cycle
Number of subjects: 11
Study 32940089 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst Wave Lithotripsy
Number of subjects: 0
Study 32940089 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32940537 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery System
Number of subjects: 0
Study 32940955 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for 50 exposure days (~26 weeks)
Number of subjects: 68
Study 32940955 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for a median time of ~4.9 years
Number of subjects: 68
Study 32941200 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary neprilysin levels on postoperative day 1
Number of subjects: 96
Study 32941200 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary neprilysin levels at the end of surgery
Number of subjects: 96
Study 32941200 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminatory power of neprilysin for detecting early AKI
Number of subjects: 96
Study 32941647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic transplantation
Number of subjects: 35
Study 32941876 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cadmium levels (58 ng/L median)
Number of subjects: 672
Study 32941876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiles of plasma cadmium (13, 26, and 39 events of graft failure)
Number of subjects: 672